DUSSELDORF, Germany, Aug. 1 /CNW/ -
- Further Focus on Pharma & Life Science
Gerresheimer AG is to discontinue its business in technical plastic
systems. The business segment, which primarily manufactures system components
for suppliers to the automobile industry, is not part of the core business of
pharma & life science. For this purpose the sale process has been started
through an international invitation for bids.
"Through the sale of the technical plastics business we are, as
previously announced, continuing our focus on the core business of pharma &
life science," says Dr. Axel Herberg, CEO of Gerresheimer AG.
In the segment of technical plastic systems, Gerresheimer employs 550
people at locations in Germany, the Czech Republic and Mexico as well as
through joint ventures in Italy and Bulgaria, manufacturing system components
for suppliers to the automobile industry. The main product focus is on vehicle
electrics, powertrain and chassis as well as interior. Sales of around EUR 70m
are expected for this segment in the financial year 2008.
Gerresheimer acquired the technical plastics business in 2007 as part of
the Wilden Group. While the Wilden Group's business in medical plastic systems
has today been firmly integrated in the Gerresheimer Group's portfolio, the
technical plastics segment does not belong to Gerresheimer's core business in
pharma & life science. Through the sale, portfolio rationalisation in the
Plastic Systems Division will be completed.
In June this year, the Dusseldorf company already sold off its consumer
healthcare business, which also did not fit in with its core business.
Gerresheimer employs more than 10,300 people in 40 locations in Europe,
America and Asia. In the financial year 2007, worldwide sales totalled
EUR 958m. The product portfolio ranges from pharmaceutical vials made of glass
and plastic through to complex drug-delivery systems for the pharma & life
science industry. These include sterile syringes, inhalers and other
system-based approaches for safe dosage and application of medications. The
Group enjoys a leading position in markets which are characterised by high
technical and regulatory barriers.
For further information:
For further information: Contact Press: Burkhard Lingenberg, Director
Corporate PR & Marketing, Telephone: +49-211-6181-250, Telefax:
+49-211-6181-241, E-mail: email@example.com; Contact Investor
Relations: Anke Linnartz, Director Corporate Investor, Director Corporate
Investor Relations, Telephone: +49-211-6181-314, Telefax: +49-211-6181-121,